Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences
30. August 2018 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Second Quarter 2018 Financial and Operating Results
07. August 2018 16:07 ET
|
Alder BioPharmaceuticals, Inc.
- Presented new eptinezumab Phase 3 clinical trial data in episodic and chronic migraine demonstrating robust efficacy that is sustained and further improved after repeat quarterly treatments - -...
Alder BioPharmaceuticals® to Present at the Canaccord Genuity 38th Annual Growth Conference
02. August 2018 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Host Conference Call to Discuss Second Quarter 2018 Financial and Operating Results
31. Juli 2018 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., July 31, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Presents New One-Year Data for Eptinezumab from PROMISE 1 Phase 3 Trial Demonstrating Long-Term Efficacy in Episodic Migraine
29. Juni 2018 08:30 ET
|
Alder BioPharmaceuticals, Inc.
- Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate eptinezumab’s robust efficacy is further improved at one year following third and fourth quarterly...
Alder BioPharmaceuticals® Presents New Six-Month Data for Eptinezumab Demonstrating Improvement in Efficacy in PROMISE 2 Phase 3 Trial for Chronic Migraine
29. Juni 2018 08:30 ET
|
Alder BioPharmaceuticals, Inc.
- Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate 43% of patients receiving 300 mg of eptinezumab achieved a 75% or greater reduction of monthly...
Alder BioPharmaceuticals® to Present New Data Further Highlighting Eptinezumab’s Efficacy Profile for Migraine Prevention at American Headache Society Meeting
20. Juni 2018 08:30 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., June 20, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15. Juni 2018 17:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., June 15, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Names Robert W. Azelby President and Chief Executive Officer
07. Juni 2018 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., June 07, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports First Quarter 2018 Financial and Operating Results
08. Mai 2018 16:07 ET
|
Alder BioPharmaceuticals, Inc.
- 12-Month Data Presented at American Academy of Neurology (AAN) Annual Meeting Demonstrated Eptinezumab Further Reduced Migraine Risk Following Third and Fourth Quarterly Infusions - - Biologics...